Literature DB >> 23158571

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.

Rainer Claus1, Dietmar Pfeifer, Maika Almstedt, Manuela Zucknick, Björn Hackanson, Christoph Plass, Michael Lübbert.   

Abstract

In vivo effects of the DNA hypomethylating agent 5-aza-2'-deoxycytidine (DAC) upon the epigenome of acute myeloid leukemia (AML) patients are scarcely studied in primary blasts. Here, we sequentially assessed DNA methylation and transcriptome changes in myeloblasts of DAC-treated AML patients. DNA methylation changes were detected in all patients already after the first series of infusion (median: 6 days). LINE1 analysis indicated global DNA methylation decrease in 7/8 patients. Gene-specific hypomethylating effects were not directly linked to mRNA expression changes. In conclusion, complex DAC-induced DNA methylation changes occur very early and imply mechanisms distinct from non-hypomethylating cytosine analogs.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23158571     DOI： 10.1016/j.leukres.2012.10.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  15 in total

1.  Genomic impact of transient low-dose decitabine treatment on primary AML cells.

Authors:  Jeffery M Klco; David H Spencer; Tamara L Lamprecht; Shawn M Sarkaria; Todd Wylie; Vincent Magrini; Jasreet Hundal; Jason Walker; Nobish Varghese; Petra Erdmann-Gilmore; Cheryl F Lichti; Matthew R Meyer; R Reid Townsend; Richard K Wilson; Elaine R Mardis; Timothy J Ley
Journal:  Blood       Date:  2013-01-07       Impact factor: 22.113

2.  Combined analysis of DNA methylation and cell cycle in cancer cells.

Authors:  Cécile Desjobert; Mounir El Maï; Tom Gérard-Hirne; Dominique Guianvarc'h; Arnaud Carrier; Cyrielle Pottier; Paola B Arimondo; Joëlle Riond
Journal:  Epigenetics       Date:  2015-01-23       Impact factor: 4.528

Review 3.  Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer.

Authors:  Christoph Plass; Stefan M Pfister; Anders M Lindroth; Olga Bogatyrova; Rainer Claus; Peter Lichter
Journal:  Nat Rev Genet       Date:  2013-10-09       Impact factor: 53.242

Review 4.  The mechanistic role of DNA methylation in myeloid leukemogenesis.

Authors:  J Jasielec; V Saloura; L A Godley
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

5.  Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.

Authors:  Nicholas J Achille; Megan Othus; Kathleen Phelan; Shubin Zhang; Kathrine Cooper; John E Godwin; Frederick R Appelbaum; Jerald P Radich; Harry P Erba; Sucha Nand; Nancy J Zeleznik-Le
Journal:  Leuk Res       Date:  2016-01-15       Impact factor: 3.156

6.  Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.

Authors:  Sarah M Leonard; Tracey Perry; Ciarán B Woodman; Pamela Kearns
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

7.  DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML.

Authors:  Kirstin Lund; John J Cole; Nathan D VanderKraats; Tony McBryan; Nikolay A Pchelintsev; William Clark; Mhairi Copland; John R Edwards; Peter D Adams
Journal:  Genome Biol       Date:  2014-08-30       Impact factor: 13.583

8.  Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.

Authors:  Richard L Momparler; Sylvie Côté; Louise F Momparler; Youssef Idaghdour
Journal:  Clin Epigenetics       Date:  2014-10-01       Impact factor: 6.551

9.  A WIMSical approach to decoding DNA methylation in myeloid leukemia.

Authors:  Olga A Guryanova; Ross L Levine
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

10.  CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.

Authors:  Christoph Plass; Christian Flotho; Silvia Fluhr; Melanie Boerries; Hauke Busch; Aikaterini Symeonidi; Tania Witte; Daniel B Lipka; Oliver Mücke; Peter Nöllke; Christopher Felix Krombholz; Charlotte M Niemeyer
Journal:  Clin Epigenetics       Date:  2016-05-05       Impact factor: 6.551
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.